Advertisement Asterand names new board member - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Asterand names new board member

Asterand, a provider of human tissue and services to pharmaceutical companies engaged in drug discovery research, has appointed John Stchur to its board as an executive director. Mr Stchur will continue as the company's CFO.

Mr Stchur joined Asterand in 2002 and led the company through two rounds of venture funding and listing on the London Stock Exchange by means of a reverse merger (with Pharmagene) to form Asterand in January 2006. He was appointed CFO and corporate secretary of the new group in 2007.

Jack Davis, chairman of Asterand, said: “I’m pleased to welcome John to the board. His leadership and exceptional management of the company’s finances have been key factors in our growth.

“John is a talented business leader with extensive knowledge of Asterand’s markets and operations. I am confident that John’s contribution will be invaluable as we continue to pursue our strategic objectives of sustained profitability and future growth.”